Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals Cell and Genetic Therapies chief and executive vice-president Bastiano Sanna said: “We have multiple programmes in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune programme, in preclinical development.

Gene Editing 235

Gene Editing Gene DNA Gene Therapy 235

Pharmaceutical Technology

JUNE 29, 2022

For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. Developing best-in-class speciality enzymes.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

Scienmag

JUNE 7, 2021

Credit: ETH Zurich Many modern fitness trackers and smartwatches feature integrated LEDs. The green light emitted, whether continuous or pulsed, penetrates the skin and can be used to measure the wearer’s heart rate during physical activity or while at rest. These watches have become extremely popular.

Insulin 95

Insulin Production Research Gene Therapy 95

Delveinsight

DECEMBER 10, 2020

The body’s immune system falsely attacks insulin-making beta cells in the pancreas in Type 1 diabetes. UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3. Its recent data infer that it could work for patients considered unsuited for gene therapy. The protein is known as OCA-B.

Gene Therapy 52

Gene Therapy Gene Vaccination Vaccine 52

Pharma Packaging Solutions

JUNE 30, 2023

Hormones (such as insulin, glucagon, and growth hormone, to name a few) are produced by recombinant DNA, as are blood factors, thrombolytic agents, interferons, monoclonal antibodies, therapeutic enzymes, and more.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

XTalks

JANUARY 21, 2025

There, plasma is separated, and tumor DNA is identified by detecting genetic mutations, methylation patterns and fragmentation signals. Companion diagnostic for Pfizers hemophilia B gene therapy Beqvez (idanacogene elaparvovec-dzkt). The genetic bleeding disorder is caused by the absence of blood clotting factor IX.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

BioSpace

NOVEMBER 17, 2022

Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.

Gene Therapy 42

Gene Therapy Gene Gene Editing Medicine 42